S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Urgent Warning (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Urgent Warning (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Urgent Warning (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Urgent Warning (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Urgent Warning (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Urgent Warning (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Urgent Warning (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Urgent Warning (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Urgent Warning (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Urgent Warning (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Urgent Warning (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Urgent Warning (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 

Enlivex Therapeutics - ENLV Competitors

$3.66
+0.10 (+2.81%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.50
$3.75
50-Day Range
$3.55
$4.55
52-Week Range
$3.42
$8.64
Volume
23,490 shs
Average Volume
25,945 shs
Market Capitalization
$67.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

ENLV vs. SEEL, VIRX, ASMB, ANEB, GRTX, NCNA, ADAG, SYRS, BLPH, and CNTB

Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Seelos Therapeutics (SEEL), Viracta Therapeutics (VIRX), Assembly Biosciences (ASMB), Anebulo Pharmaceuticals (ANEB), Galera Therapeutics (GRTX), NuCana (NCNA), Adagene (ADAG), Syros Pharmaceuticals (SYRS), Bellerophon Therapeutics (BLPH), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical preparations" industry.

Enlivex Therapeutics vs.

Enlivex Therapeutics (NASDAQ:ENLV) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Seelos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enlivex TherapeuticsN/AN/A-$14.47 million-$1.56-2.35
Seelos TherapeuticsN/AN/A-$66.05 million-$0.79-0.87

Enlivex Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Seelos Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500.

Seelos Therapeutics received 24 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 77.59% of users gave Enlivex Therapeutics an outperform vote while only 69.70% of users gave Seelos Therapeutics an outperform vote.

CompanyUnderperformOutperform
Enlivex TherapeuticsOutperform Votes
45
77.59%
Underperform Votes
13
22.41%
Seelos TherapeuticsOutperform Votes
69
69.70%
Underperform Votes
30
30.30%

1.8% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 25.4% of Seelos Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 5.1% of Seelos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Enlivex Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 309.84%. Given Enlivex Therapeutics' higher probable upside, research analysts clearly believe Enlivex Therapeutics is more favorable than Seelos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enlivex Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Seelos Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Enlivex Therapeutics and Enlivex Therapeutics both had 1 articles in the media. Enlivex Therapeutics' average media sentiment score of 1.66 beat Seelos Therapeutics' score of 0.40 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enlivex Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Seelos Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Enlivex Therapeutics' return on equity of -38.86% beat Seelos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enlivex Therapeutics N/A -38.86% -34.31%
Seelos Therapeutics N/A -425.47% -157.62%

Summary

Enlivex Therapeutics beats Seelos Therapeutics on 7 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENLV vs. The Competition

MetricEnlivex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$67.38M$5.36B$4.22B$5.78B
Dividend YieldN/A2.63%6.03%4.46%
P/E Ratio-2.355.18108.6812.73
Price / SalesN/A279.803,529.9860.22
Price / CashN/A19.2026.5897.15
Price / Book0.794.084.404.92
Net Income-$14.47M$184.84M$114.67M$191.77M
7 Day Performance1.95%-2.76%-1.41%-0.52%
1 Month Performance-10.73%-13.08%-7.95%-8.13%
1 Year Performance-31.72%-12.87%-15.99%-18.29%

Enlivex Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SEEL
Seelos Therapeutics
1.0568 of 5 stars
$0.63
-10.1%
$4.00
+540.0%
-28.2%$66.98MN/A-0.7915Upcoming Earnings
Gap Up
VIRX
Viracta Therapeutics
2.1068 of 5 stars
$1.69
-3.4%
$8.00
+373.4%
-51.1%$64.56MN/A-1.2624Gap Down
ASMB
Assembly Biosciences
2.2572 of 5 stars
$1.32
+1.5%
$2.50
+89.4%
-31.3%$64.39M$6.25M-0.46102
ANEB
Anebulo Pharmaceuticals
1.8443 of 5 stars
$2.51
-6.0%
$7.00
+178.9%
-52.2%$64.34MN/A-5.702
GRTX
Galera Therapeutics
1.8934 of 5 stars
$2.23
+6.2%
$7.67
+243.8%
-8.8%$63.56MN/A-0.9730Gap Down
NCNA
NuCana
2.2766 of 5 stars
$1.21
-0.8%
$3.67
+203.0%
+23.3%$63.14MN/A-1.5927Gap Down
ADAG
Adagene
2.3661 of 5 stars
$1.60
+11.9%
$5.00
+212.5%
-67.6%$69.21M$12.74M0.00198Positive News
SYRS
Syros Pharmaceuticals
2.3694 of 5 stars
$3.09
+2.3%
$16.00
+417.8%
-76.6%$62.73M$14.88M-0.24124
BLPH
Bellerophon Therapeutics
2.049 of 5 stars
$6.44
-5.6%
$19.00
+195.0%
+256.0%$62.66MN/A-3.2221Analyst Report
CNTB
Connect Biopharma
2.3885 of 5 stars
$1.12
+3.7%
$7.00
+525.0%
-73.3%$61.65MN/A0.0062News Coverage
Positive News
Gap Up
This page (NASDAQ:ENLV) was last updated on 3/21/2023 by MarketBeat.com Staff